U.S., Feb. 21 -- ClinicalTrials.gov registry received information related to the study (NCT06837896) titled 'Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer' on Feb. 17.
Brief Summary: The purpose of this study was to evaluate the efficacy and safety of QLG1080 in patients with hormone-sensitive advanced prostate cancer.
Study Start Date: Feb., 2025
Study Type: INTERVENTIONAL
Condition:
Prostate Cancer
Intervention:
DRUG: QLG1080
Oral administration
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Qilu Pharmaceutical Co., Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....